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Background: Treatment of acne is an important issue for reducing the cosmetic and psychological burden of disease. Regarding 
the inflammatory effect of LT-B4 in acne lesions and action mechanism of Montelukast, this study was performed to determine the 
efficacy of Montelukastin acne treatment comparison with doxycycline. Materials and Methods: In a randomized clinical trial that 
was performed in Dermatology Clinic in a Training Tertiary Health Care Center in Tehran, Iran since January 2012 to May 2014, 
52 patients with moderate acne were evaluated. The included patients were randomly assigned to receive doxycycline 100 mg/day 
plus 1% Clindamycin solution (Group 1) or Montelukast 5 mg daily plus 1% clindamycin solution (Group 2). The acne severity index 
was measured and compared between two groups at baseline (on admission), 1-month and 3 months later. Independent-Sample-T, 
Chi-Square, and Repeated-Measure ANOVA tests were used and were considered statistically significant at P < 0.05. Results: The 
mean age was 26.8 ± 7.1 in Group 1 and25 ± 4.8 in Group 2 (P = 0.1). 73% women and 26.7% 4 men in Group 1 and 86.7% women, 
and 13.3% men in Group 2 (P = 0.01). The mean acne severity index at baseline was 18.2 ± 6.1 and 19 ± 4.2 in Montelukast and 
doxycycline group, respectively (P = 0.679). The mean acne severity index after 1-month was 10.5 ± 6.2 and 12.9 ± 3.3 in Montelukast 
and doxycycline group, respectively (P = 0). Finally, the mean acne severity index after 3 months follow-up was 8.6 ± 4.8 and 8.2 ± 
1.2 in Montelukast and doxycycline group, respectively (P = 0.01). There was no significant difference between two groups regarding 
the amount of decrease in acne severity index across the study (P = 0.186). However, each groups showed a significant reduction in 
the acne severity index, separately (P = 0.001). Conclusion: It may be concluded that Montelukast is an effective and safe medication 
for moderate-level acne treatment.
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Propionibacterium acnes are highly sensitive to 
many antibiotics such as doxycycline, tetracycline, 
minocycline.[2]
Tissue inflammation is also an important part of 
acne development and progressions.[3-6] On the other 
hand, the enzymes contributing for Leukotriene-B4 
(LT-B4) and prostaglandin-E2, are active in acne 
lesions.[7] LT-B4 is the product of arachidonic acid 
pathway.[8-10] Arachidonic acid would result in LT-B4 and 
IL-6 secretion and increase in lipid synthesis in sebaceous 
glands.[9] Also, LT-B4 is a natural ligand for proxisome 
proliferation activated receptor α (PPAR).[11,12] PPAR 
may modifies the inflammatory response in different 
cells with inhibition of proinflammatory genes such as 
cytokines, metaloproteins, and acute phase reactants.
[12,13] There are two ways to interrupt the leukotriene 
INTRODUCTION
Acne lesions are papulopustular affecting mainly the 
face, chest, and back regions. Acne is usually initiated 
in age range from 10 to 15 years lasting for 5 to 
10 years.[1] However, it may be extended to later ages. 
The sebaceous glands obstruction, increased sebum 
formation, and propionibacterium acne are the most 
important contributing factors. Current medications 
for acne include Tretinoin and its preparations, benzoyl 
peroxide, and local and systemic antibiotics.[1]
Doxycycline acts on inflammatory acne. The bacteria are 
usually present in small numbers. Propionibacterium 
acne proliferates in the lipid rich environment of 
the microcomedo and produces proinflammatory 
mediators that cause papules, pustules and cysts. 
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pathway and prevention from its effect; first inhibition of 
5-lipooxygenase and reduction of leukotriene synthesis and 
the second way is prevention of bonding between LT-B4 and 
related receptor on target organs. Drugs such as zafirlukast 
and Montelukast are antagonists of LT-B4 receptor.[14] Many 
studies demonstrated the effectiveness of Montelukast in 
allergic disorders due its immunomodulatory effect.[15-17] 
In addition, some evidence showed Montelukast therapy 
can be useful in the treatment of some skin disorder such 
as atopic dermatitis, chronic idiopathic urticarial and 
pemphigoid nodularis.[18-20]
Although many studies have shown the efficacy of 
doxycycline in the treatment of acne, it is associate with 
some side effects. Side effects caused by doxycycline are 
gastrointestinal irritation with diarrhea, vomiting, and 
dyspepsia. Vaginal candidiasis may occur in women 
and the influence when on the pill is not certain, giving 
recommendations to be extra cautious with contraceptives 
during therapy.[21,22] One particularly evident side effect 
in children is the potential yellowish discoloration and 
enamel hypoplasia of the developing teeth’s.[21,23] Rare 
adverse effects are benign intracranial hypertension and 
photosensitivity.[23] Regarding the inflammatory effect of 
LT-B4 in acne lesions and action mechanism of Montelukast, 
this study was performed to determine the efficacy of this 
drug in acne treatment and comparison with doxycycline 
as a pilot study.
MATERIALS AND METHODS
In this randomized clinical trial that was performed as pilot 
study, 52 consecutive patients attending to Dermatology 
Clinic in a Training Tertiary Health Care Center in Tehran, 
Iran since January 2012 to May 2014 were enrolled. This 
study was approved by Local Ethical Committee with 
number 1076 and Helsinki declaration was respected all 
over the study course. Patients were randomly allocated 
to receive doxycycline Hakim factory, Iran.100 mg/day 
plus 1% Clindamycin solution (Pakdaro factory, Iran) or 
Montelukast 5 mg (Aboreyhan factory, Iran) daily plus 
1% Clindamycin solution for 3 months. The duration of 
treatment was 3 months). The dose of 5 mg Montulukast 
was selected (half dose of routine dosage of asthma) in this 
pilot study.[15]
Patients were evaluated on admission, both 1-month and 
3-months after treatment. The moderate acne severity, 
lack of background disease, and lack of other treatments 
in previous month were the inclusion criteria and major 
drug reaction and impossibility of follow-up and lack of 
satisfaction for incorporation in the study were the exclusion 
criteria. The acne severity index[2] was measured and 
recoded by single, blind dermatologist and was compared 
across the study between two groups. Acne vulgaris was 
graded by Indian authors[16] using a grading system, which 
classifies acne lesions to 4 groups. Each type of lesion 
is given a value depending on severity: Nolesions = 0, 
comedones = 1, papules = 2, pustules = 3 and nodules = 4. The 
factor for each area include (Forehead: 2, Right cheek: 2, Left 
cheek: 2, Nose: 1 Chin: 1, Chest and upper back: 3. (Local 
score) is calculated using the formula: Localscore = Factor × 
Grade (0-4). The global score is the sum of local scores, acne 
severity was graded using the global score. A score of 1-18 
is considered mild; 19-30, moderate; 31-38, severe; and >39, 
very severe. The mean acne index before treatment, The 
mean in case group 12.8 and 10.5 in control group 1-month 
after treatment and 8.2 in case group, 8.6 in control group 
3 months after treatment (P = 0.01) in case group was 19.2 
and in control group 18.2 (P = 0.01). Liver function test was 
performed for all patients after 3 months for possible side 
effect. We didn’t select a third group using only clindamycin 
group because for treatment of moderate acne systemic 
therapy is essential, and topical therapy is not enough 
20 patients were excluded from the study. The analysis 
was performed among 30 subjects including 15 patients 
in doxycycline group and 15 subjects in Montelukast 
group. Data analysis was performed by SPSS (version 
20.0) software [Statistical Procedures for Social Sciences; 
Chicago, Illinois, USA]. Independent-Sample-T, Chi-Square, 
and Repeated-Measure ANOVA tests were used and were 
considered statistically significant at P < 0.05.
RESULTS
The patients included 24 female (80%) and six male subjects 
(20%). In Montelukast and doxycycline groups, 13 and 
11 female patients were present (P = 0.651). The mean age 
was 26.87 ± 7.10 and 25 ± 4.88 years in Montelukast and 
doxycycline group, respectively (P = 0.410).
Figure 1: Acne severity index in two groups across the study at baseline (1), 
after one month (2), and after three months (3). The green line is related to 
Montelukast group and the blue one is for doxycycline
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As shown in Figure 1, the mean acne severity index at 
baseline was 18.2 ± 6.1 and 19 ± 4.2 in Montelukast and 
doxycycline group, respectively (P = 0.679). The mean acne 
severity index after 1-month was 10.5 ± 6.2 and 12.9 ± 3.3 in 
Montelukast and doxycycline group, respectively (P = 0.001. 
Finally, the mean acne severity index after 3 months was 
8.6 ± 4.8 and 8.2 ± 1.2 in Montelukast and doxycycline group, 
respectively. P = 0.001, P = 0.001). Each groups showed a 
significant reduction in acne severity index, separately 
(P = 0.001) during follow-up times. None of the patients 
in Montelukast group had drug adverse effects, but two 
patients in doxycycline groups developed dyspepsia 
leading to exclusion from the study. All included patients 
had normal function test after 3 months
DISCUSSION
This pilot study was performed to determine the efficacy 
of Montelukast in acne treatment and comparison with 
doxycycline in a 12-week course of treatment Tissue 
inflammation has major rolein the acne process. LTB (4) 
is considered to have major effect on the development of 
tissue inflammation. Synthesis of LTB (4) is by the enzyme 
5-lipoxygenase. Since Zileuton blocks the activity of 
5-lipoxygenase, clinical studies have been conducted to test 
function, as well as efficacy and safety of this compound in 
the treatment of acne vulgaris, so we decide to do a study 
with Montelukast that blocks leukotriene receptors with 
half dose of its use in asthma treatment. However, in both 
groups, the local Clindamycin was also prescribed for all 
the patients. The obtained results demonstrate the efficacy 
of LT-B4 inhibition in the treatment of acne lesions as well 
as previous studies. In a pilot clinical study with 10 patients 
with papulopustular acne Zileuton 4 × 600 mg/d p.o. for 
3 months decreased the acne severity index in a time-
dependent manner being 41% of the initial score at week 12 
(P < 0.05). This was mostly due to a decrease of the number 
of inflammatory lesions of 29% (P < 0.01). Moreover, total 
sebum lipids significantly decreased (35%, P < 0.05) and the 
pro-inflammatory free fatty acids (22%) and lipoperoxides 
(26%) were markedly diminished in patients’ sebum under 
treatment. These data are in agreement with clinical study 
in 101 patients with mild to moderate inflammatory facial 
acne conducted in the US, which showed a significant 
efficacy of Zileuton in patients with moderate acne, whereas 
those patients treated with Zileuton showed a significant 
mean decrease in inflammatory lesions compared to the 
placebo group. In all clinical studies, Zileutonwas found to 
be safe and well tolerated.[24] In other pilot study, 16 female 
patients with a diagnosis of sebaceous hyperplasia were 
compared to a control group of females of a similar 
age without the disease. Blood tests were performed 
to measure circulating androgen levels (free and total 
testosterone and androstenedione levels). These data 
showed no statistically differences in circulating androgen 
levels between the patients with sebaceous hyperplasia and 
the control group; therefore, there is no significant changes 
in circulating androgen levels (free and total testosterone, 
androstenedione, dehydroepiandrosterone (DHEA) and 
DHEA sulfate) in patients with sebaceous hyperplasia.[25]
In our study, since the acne severity index was reduced in 
both groups, it may be concluded that both medications are 
effective. However, the efficacy was same across the groups, 
and there was no significant difference. Also despite the 
lack of difference in rate of drug adverse effects across the 
groups, there were no case versus two cases of side effects 
in doxycycline group. Use of nonantibiotic medications, 
regarding the increased rate of anti-microbial resistance, is 
rational especially if there are drugs with good efficacy and 
high safety such as Montelukast as shown in the current 
study.
The main limitation in this study was low patients’ 
compliance and also high rate of subjects lost to follow-up. 
Also, this study was performed as a pilot trial and further 
studies with larger sample size should be carried out to 
obtain more definite results. Also, we could not completely 
evaluate for possible confounding factors, and only the 
age and gender were studied in currents trial leading to 
decreased applicability of the obtained results. Also, there 
was an inevitable limitation in this study; there were no 
similar reports in this era to be compared.
Finally, according to the obtained results in this study, it may be 
concluded that Montelukast is an effective and safe medication 
for acne treatment. Accordingly use of this drug is recommended 
especially in cases with moderate-level acne. Further studies 
with longer follow-up sessions would let to decide better about 
the efficacy of Montelukast and related safety.
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